The courts have once again found that drug manufacturer, Johnson & Johnson, failed to warn consumers of the risks of suffering Risperdal® side effects while using the medication. Reports indicate this is the third trial the company has lost involving the drug and they could be facing many more legal battles regarding the drug in the future.
A jury in a Philadelphia courtroom found that a young man suffered from Gynecomastia—a hormonal condition in which male patients develop breast tissue—as a result of taking Risperdal. The jury ordered Johnson & Johnson to pay $1.75 million in damages to the victim.
Evidence in this case and others like it have shown Johnson & Johnson failed to warn the public of the risks of developing the disease as a result of taking Risperdal. In fact, corrective action wasn’t taken in the matter until five years after the company was first made aware of the issue. The company has also come under scrutiny for off-label marketing of the drug to young patients.
While decisions and settlements have been reached in a number of lawsuits stemming from Risperdal side effects, an article from FiercePharma explains officials say Johnson & Johnson and its subsidiaries could still face as many as 1,500 claims stemming from harm patients suffered as a result of taking the drug.
The legal staff at Fleschner, Stark, Tanoos & Newlin recognize how devastating Risperdal side effects can be to the lives of the victims, and we’re hopeful the decisions that have been reached in these drug injury lawsuits have brought peace and closure to those who were harmed.
Fleschner, Stark, Tanoos & NewlinN/a
The financial burden that often comes with a serious injury can be too much for many people to bear. Unexpected medical debt, damaged personal property, and the sudden loss of income can impact the budgets of most families. The good news is that a successful injury claim could help reduce that financial strain after a serious accident. Get in touch with a Terre Haute personal injury lawyer with Fleschner, Stark, Tanoos & Newlin to learn more.
© Fleschner, Stark, Tanoos & Newlin